This is old news, that article is from July.
Yes, but it was never published in the forum and I consider that the information can be very useful.
It is published, a lot of people were discussing about it, the ceo said it’s due to covid 19 placebo effect
If so I delete it. Because the article not only talks about Ulotaront but also about Roluperidone. He says this information.
‘‘Along with ulotaront, psychiatrists are also hopeful that other experimental drugs will offer stepwise improvements in schizophrenia treatment, including Minerva Pharma’s roluperidone (MIN-101), which has been shown to block serotonin, sigma, and α-adrenergic receptors.’’
''Roluperidone also failed a phase 3 trial in 2020 but subsequently showed evidence that it may be able to target the negative symptoms of schizophrenia – such as apathy and social withdrawal – that remain resistant to treatment with current drugs.
The drug was filed with the FDA, and while initially the regulator refused to accept the marketing application, a review has since started with a decision due by 26th February next year.‘’